Table 3.

Multivariate analysis of prognostic factors using the Cox-regression model (including biologic factors).

Variables	BCSS		OS
	HR (95% CI)	P	HR (95% CI)	P
Age (years)
≥50 vs. <50	1.070(0.743–1.543)	0.715	1.465(1.062–2.019)	0.020
Race/ethnicity
Non-Hispanic Black vs. Non-Hispanic White	1.223(0.790–1.895)	0.367	1.272(0.865–1.870)	0.222
Hispanic (All Races) vs. Non-Hispanic White	0.736(0.396–1.369)	0.333	1.015(0.615–1.676)	0.953
Other vs. Non-Hispanic White	0.784(0.401–1.532)	0.476	0.761(0.415–1.398)	0.379
Histology
ILC vs. IDC	2.567(1.278–5.155)	0.008	2.339(1.275–4.292)	0.006
Other vs. IDC	0.791(0.421–1.484)	0.465	0.870(0.527–1.438)	0.587
Histologic grade
G2 vs. G1	1.638(0.375–7.148)	0.512	0.724(0.309–1.697)	0.458
G3 vs. G1	4.932(1.169–20.804)	0.030	1.741(0.768–3.947)	0.184
T category
T2 vs.T1	0.462(0.263–0.813)	0.007	0.698(0.430–1.133)	0.146
T3 vs.T1	1.235(0.727–2.099)	0.434	1.202(0.732–1.975)	0.466
T4 vs.T1	1.172(0.675–2.034)	0.573	1.368(0.834–2.246)	0.215
HER2 status
Positive vs. Negative	0.588(0.385–0.899)	0.014	0.549(0.376–0.802)	0.002
ER status
Positive vs. Negative	0.640(0.440–0.931)	0.020	0.568(0.408–0.793)	0.001
PR status
Positive vs. Negative	0.779(0.474–1.281)	0.326	0.747(0.484–1.155)	0.190

ILC, infiltrating lobular carcinoma; IDC, infiltrating ductal carcinoma; BCS, breast-conserving surgery; BCSS, breast cancer-specific survival; ER, estrogen receptor; G1, well-differentiated; G2, moderately differentiated; G3, poorly/undifferentiated; HER2, human epidermal growth factor receptor-2; MAST, mastectomy; OS, overall survival; RT, radiotherapy; PR, progesterone receptor; T, tumor.